Abstract
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with unclear mechanisms of pathogenesis. Gastrointestinal microbiome alterations were found to correlate with ASD core symptoms, but its specific role in ASD pathogenesis has not been determined. In this study, we used a case-control strategy that simultaneously compared the ASD gastrointestinal microbiome with that from age-sex matched controls and first-degree relative controls, using a statistical framework accounting for confounders such as age. Enterobacteriaceae (including Escherichia/Shigella) and Phyllobacterium were significantly enriched in the ASD group, with their relative abundances all following a pattern of ASD > first degree relative control > healthy control, consistent with our hypothesis of living environment and shared microbial and immunological exposures as key drivers of ASD gastrointestinal microbiome dysbiosis. Using multivariable omnibus testing, we identified clinical factors including ADOS scores, dietary habits, and gastrointestinal symptoms that covary with overall microbiome structure within the ASD cohort. A microbiome-specific multivariate modeling approach (MaAsLin2) demonstrated microbial taxa, such as Lachnoclostridium and Tyzzerella, are significantly associated with ASD core symptoms measured by ADOS. Finally, we identified alterations in predicted biological functions, including tryptophan and tyrosine biosynthesis/metabolism potentially relevant to the pathophysiology of the gut-brain-axis. Overall, our results identified gastrointestinal microbiome signature changes in patients with ASD, highlighted associations between gastrointestinal microbiome and clinical characteristics related to the gut-brain axis and identified contributors to the heterogeneity of gastrointestinal microbiome within the ASD population.
Introduction
The "gut-brain axis" has emerged as a critical area of neurodevelopmental research, yet the precise relationship between the gastrointestinal (GI) microbiome and Autism Spectrum Disorder (ASD) remains complex. ASD is highly heterogeneous, making it difficult to distinguish autism-specific microbial signals from environmental "noise" such as diet, age, and shared living environments. This study aims to move beyond simple taxonomic catalogs to understand how specific clinical features—such as social affect and repetitive behaviors—correlate with microbiome structure and predicted metabolic functions.
Methods and Materials
The researchers employed a robust "double control" case-control strategy involving 119 participants:
- ASD Group: 39 children aged 3–6.
- Healthy Age-Sex Matched Controls (HC): 44 unrelated peers.
- First-Degree Relative Controls: 36 individuals (mostly mothers) to account for shared genetics and environment.
Clinical severity was assessed using the Autism Diagnostic Observation Schedule (ADOS), Social Responsiveness Scale (SRS), Gastrointestinal Severity (GIS) index, and Repetitive Behavior Scale-Revised (RBS-R). Technical analysis included 16S rRNA sequencing (V4-V5 regions), MaAsLin2 for multivariate association modeling, PICRUSt for functional prediction, and SparCC for co-abundance network construction.
Results
Microbial Diversity and Taxonomic Gradients
The study identified a significant "environmental gradient" in several taxa. Enterobacteriaceae (including E. coli) and Phyllobacterium followed a distinct abundance pattern: ASD > First-degree relative > Healthy control. This suggests that while shared environments influence the microbiome, the ASD state significantly amplifies these shifts.
Beta diversity analysis showed that community structure differed significantly between groups, explaining approximately 6% of the variation ($P < 0.05$). Within the ASD group, lower alpha diversity (Shannon Index) was significantly correlated with higher ADOS scores, indicating that reduced microbial diversity is associated with greater symptom severity.
Clinical Correlates and Biomarkers
Multivariate modeling (MaAsLin2) revealed that Lachnoclostridium and Tyzzerella were positively associated with ASD core symptoms. Conversely, the beneficial genus Akkermansia was significantly depleted in the ASD cohort. ADOS Social Affect scores and GI symptom severity were identified as the strongest predictors of overall microbiome structure.
Predicted Metabolic Dysregulation
Functional analysis via PICRUSt suggested significant shifts in the metabolic capabilities of the ASD microbiome. Specifically, there was a move away from the biosynthesis of tryptophan and tyrosine toward their metabolism and degradation.
As these amino acids are essential precursors for neurotransmitters like serotonin and dopamine, these findings suggest a potential biochemical mechanism linking gut dysbiosis to altered brain function in ASD.
Discussion
This study highlights the interplay between the GI microbiome and neurobehavioral outcomes in ASD. The identification of a microbial gradient across controls and the link between specific taxa and symptom severity provide new insights into the gut-brain axis.
However, several limitations remain. The cohort size (N=119) and geographic focus (China) may limit the generalizability of these findings. Furthermore, 16S sequencing provides only predicted functional data. Future research utilizing shotgun metagenomics and direct metabolomic analysis of blood and stool is necessary to confirm these metabolic shifts. The authors also suggest that using age-matched siblings as controls in future studies could better isolate the effects of the ASD phenotype from age-related microbiome development.
Summary updated